[1]孔庆旭,陈桂云,陈自力,等.槲芪方加减对肝癌化疗栓塞术后大鼠一氧化氮合酶、血管内皮生长因子、乏氧及免疫功能的影响[J].陕西中医,2024,(2):181-186.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.007]
　KONG Qingxu,CHEN Guiyun,CHEN Zili,et al.Effects of Huqi formula on iNOS,VEGF,hypoxia and immune function of rats after chemoembolization for liver cancer[J].,2024,(2):181-186.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.007]
点击复制

槲芪方加减对肝癌化疗栓塞术后大鼠一氧化氮合酶、血管内皮生长因子、乏氧及免疫功能的影响
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2024年2期
页码:
181-186
栏目:
基础研究
出版日期:
2024-02-05

文章信息/Info

Title:
Effects of Huqi formula on iNOS,VEGF,hypoxia and immune function of rats after chemoembolization for liver cancer
作者:
孔庆旭1; 陈桂云1; 陈自力1; 李 俊2
(1.钟祥市中医院,湖北 钟祥 431900; 2.安徽医科大学附属医院,安徽 合肥230032)
Author(s):
KONG Qingxu; CHEN Guiyun; CHEN Zili; LI Jun
(Zhongxiang Hospital of Traditional Chinese Medicine,Zhongxiang 431900,China)
关键词:
肝癌;  肝癌化疗栓塞术;  槲芪方;  大鼠;  一氧化氮合酶;  血管内皮生长因子;  乏氧;  免疫功能
Keywords:
Liver cancer;  Chemoembolization for liver cancer;  Huqi formula;  Rats;  Inducible nitric oxide synthase;  Vascular epidermal growth factor;  Anoxia;  Immune function
分类号:
R 256.4
DOI:
DOI:10.3969/j.issn.1000-7369.2024.02.007
文献标志码:
A
摘要:
目的:研究槲芪方加减对肝癌化疗栓塞术后大鼠一氧化氮合酶(iNOS)、血管内皮生长因子(VEGF)、乏氧及免疫功能的影响。方法:50只大鼠中随机抽取12只作为健康组进行对照,37只大鼠建立肝癌模型。建模过程中意外死亡1只大鼠,剩余36只大鼠建模成功,随机分为模型组、肝动脉化疗栓塞术组以及联合组,每组12只。肝动脉化疗栓塞术组给予肝动脉化疗栓塞术(TACE)治疗; 联合组在肝动脉化疗栓塞术组基础上给予模型大鼠27 ml/kg槲芪方灌胃,2次/d,共24周。运用全自动生化分析仪检测各组大鼠肝功能指标水平,流式细胞仪检测各组大鼠免疫功能指标水平,苏木精-伊红(HE)染色观察各组大鼠肝组织病理变化,原位末端标记法(TUNEL)检测各组大鼠肝癌细胞凋亡,免疫印迹检测各组大鼠VEGF、iNOS、缺氧诱导因子1α(HIF-1α)蛋白表达。结果:与健康组比较,模型组丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、碱性磷酸酶(ALP)水平均升高(P<0.05),与模型组比较,肝动脉化疗栓塞术组ALT、AST、ALP水平均降低(P<0.05),肝动脉化疗栓塞术组ALT、AST、ALP水平均高于联合组(P<0.05)。与健康组比较,模型组CD3+、CD4+、CD4+/CD8+降低,CD8+升高(P<0.05),模型组与联合组比较差异无统计学意义(P>0.05),与模型组及联合组比较,肝动脉化疗栓塞术组CD3+、CD4+、CD4+/CD8+降低,CD8+升高(P<0.05)。与健康组比较,模型组细胞凋亡率升高(P<0.05),与模型组比较,肝动脉化疗栓塞术组细胞凋亡率降低(P<0.05),肝动脉化疗栓塞术组细胞凋亡率低于联合组(P<0.05)。与健康组比较,模型组VEGF、iNOS、HIF-1α表达均升高(P<0.05),与模型组比较,肝动脉化疗栓塞术组VEGF、iNOS、HIF-1α表达均升高(P<0.05),与肝动脉化疗栓塞术组比较,联合组VEGF、iNOS、HIF-1α表达均降低(P<0.05)。结论:槲芪方加减可提高肝癌TACE术后大鼠的免疫功能,通过抑制肝癌大鼠乏氧微环境中HIF-1α、iNOS及VEGF水平,改善乏氧微环境,促进肿瘤细胞凋亡。
Abstract:
Objective:To investigate the effects of Huqi formula plus-minus on inducible nitric oxide synthase(iNOS),vascular endothelial growth factor(VEGF),hypoxia,and immune function in rats with liver cancer after chemotherapy embolization.Methods:Fifty rats were randomly selected,with 12 rats used as the healthy control group,and 37 rats were used to establish a liver cancer model.During the modeling process,one rat died unexpectedly,leaving 36 rats for successful modeling.They were randomly divided into the model group,the hepatic artery chemoembolization group,and the combination group,with 12 rats in each group.The hepatic artery chemoembolization group received hepatic artery chemoembolization(TACE)treatment; the combination group received oral administration of 27 ml/kg of Huqi formula twice a day for a total of 24 weeks on the basis of the hepatic artery chemoembolization group.The levels of liver function indicators in each group of rats were detected using an automatic biochemical analyzer,and the levels of immune function indicators were detected using flow cytometry.The pathological changes of liver tissues in each group of rats were observed by hematoxylin-eosin(HE)staining,and the apoptosis of liver cancer cells in each group of rats was detected using the terminal deoxynucleotidyl transferase dUTP nick end labeling(TUNEL)method.The protein expression of VEGF,iNOS,and hypoxia-inducible factor 1α(HIF-1α)in each group of rats was detected by immunoblotting.Results:Compared with the healthy control group,the levels of alanine aminotransferase(ALT),aspartate aminotransferase(AST),and alkaline phosphatase(ALP)in the model group increased(P<0.05).Compared with the model group,the levels of ALT,AST,and ALP in the hepatic artery chemoembolization group were decreased(P<0.05),but the levels in the hepatic artery chemoembolization group were higher than those in the combination group(P<0.05).Compared with the healthy control group,the levels of CD3+,CD4+,and CD4+/CD8+ in the model group decreased,while the level of CD8+ increased(P<0.05).There was no statistical difference in these indicators between the model group and the combination group(P>0.05).Compared with the model group,the levels of CD3+,CD4+,and CD4+/CD8+ in the hepatic artery chemoembolization group decreased,while the level of CD8+ increased(P<0.05).Compared with the healthy control group,the apoptosis rate in the model group were increased(P<0.05).Compared with the model group,the apoptosis rate in the hepatic artery chemoembolization group decreased(P<0.05),but the apoptosis rate in the hepatic artery chemoembolization group was lower than that in the combination group(P<0.05).Compared with the healthy control group,the expression of VEGF,iNOS,and HIF-1α in the model group were increased(P<0.05).Compared with the model group,the expression of VEGF,iNOS,and HIF-1α in the hepatic artery chemoembolization group were increased(P<0.05),while the expression in the combination group was decreased(P<0.05).Conclusion:Huqi formula can improve the immune function of rats after TACE operation,improve the hypoxic microenvironment and promote tumor cell apoptosis by inhibiting the levels of HIF-1α,iNOS and VEGF in hypoxic microenvironment of rats.

参考文献/References:

[1] 刘鹏,陈青山,杨建波,等.柴胡疏肝散加减联合射频消融治疗肝癌疗效研究[J].陕西中医,2023,44(7):892-896.
[2] 杨怀龙,钟唐力.DynaCT在原发性肝癌患者经肝动脉化疗栓塞术中的指导作用及对疗效的评估价值[J].临床肝胆病杂志,2022,38(4):851-856.
[3] 银艳桃.参灵方对原发性肝癌患者肝动脉化疗栓塞术后免疫功能的影响[D].南宁:广西中医药大学,2021.
[4] 陶晶,姚慧欣,孙涛,等.内皮抑素联合肝动脉化疗栓塞术对肝癌患者血清血管内皮生长因子及乏氧诱导因子-1α表达的影响[J].医疗装备,2018,31(22):3-4.
[5] WU T,YAO Y,SUN R,et al.Arterial instillation of rapamycin in treatment of rabbit hepatic xenograft tumors and its effects on VEGF,iNOS,HIF-1α,Bcl-2,Bax expression and microvessel density[J].Sci Prog,2021,104(3):368504211026417.
[6] OKIKAWA S,MORINE Y,SAITO Y,et al.Inhibition of the VEGF signaling pathway attenuates tumor associated macrophage activity in liver cancer[J].Oncol Rep,2022,47(4):71.
[7] ZHAO Y,ZHANG C,ZHANG Y,et al.Effects of image-guided adaptive radiotherapy combined with hepatic artery chemoembolization in primary liver cancer patients[J].Clin Res Hepatol Gastroenterol,2022,46(5):101889.
[8] 郭宇轩.膈下逐瘀汤治疗肝癌TACE术化疗栓塞综合征(气滞血瘀型)的临床研究[D].长沙:湖南中医药大学,2021.
[9] 冯兵,贺嵩敏,郑广娟,等.罗勒胶囊对大鼠移植性肝癌经肝动脉化疗栓塞术后骨桥蛋白和诱导性一氧化氮合酶表达的影响[J].中国实验方剂学杂志,2011,17(24):154-158.
[10] 张亮,杨晋翔,李秀惠,等.槲芪方加减对原发性肝癌正气不足、毒瘀内结证患者肝动脉化疗栓塞术后生活质量影响的回顾性队列研究[J].中医杂志,2019,60(4):306-310.
[11] 王军,徐建良,杜燕红,等.扶正祛邪汤对肝癌模型大鼠肠道菌群微生态环境的作用研究[J].陕西中医,2021,42(2):143-147.
[12] 陈萍,马小平,蔡爽,等.过表达叉头盒F1对肝癌细胞增殖、周期和凋亡的影响及机制实验研究[J].陕西医学杂志,2023,52(9):1145-1149.
[13] COWMAN S J,KOH M Y.Revisiting the HIF switch in the tumor and its immune micro environment[J].Trends Cancer,2022,8(1):28-42.
[14] HAN Z,DONG Y,LU J,et al.Role of hypoxia in inhibiting dendritic cells by VEGF signaling in tumor microenvironments:Mechanism and application[J].Am J Cancer Res,2021,11(8):3777-3793.
[15] 戚新春,易建华.长链非编码RNA BCYRN1对脑胶质瘤大鼠HIF-1α/VEGF信号通路和血管生成的作用机制[J].陕西医学杂志,2023,52(4):376-379.
[16] 邓鑫,银艳桃,宋杰,等.复方斑蝥胶囊对肝动脉化疗栓塞术后患者临床疗效的影响[J].中药材,2020,43(6):1482-1485.
[17] 史传文,刘福利,梁晓东,等.罗勒胶囊对大鼠移植性肝癌TACE术后乏氧微环境中HIF-1α、VEGF及血清sICAM-1表达影响的研究[J].中国中西医结合影像学杂志,2010,8(2):100-103,92.
[18] 钱英.槲芪方治疗原发性肝癌的临证经验[J].中西医结合肝病杂志,2019,29(2):106-108.
[19] 杨倩宇,王茜,赵森,等.黄芪-莪术影响HIF-1α/VEGF抑制肺癌血管生成相关信号通路的网络药理学研究[J].中华中医药杂志,2022,37(1):425-430.
[20] 赖子君.基于VEGF-C/PI3K/AKT信号通路研究白花蛇舌草抑制大肠癌淋巴管新生的作用机制[D].福州:福建中医药大学,2017.
[21] 陈明,王旭林,邢人伟,等.早期肝癌患者细胞免疫功能、血清VEGF表达及CTC微转移与术后复发的相关性[J].重庆医学,2020,49(3):356-359,364.
[22] YANG F,XU G L,HUANG J T,et al.Transarterial chemoembolization combined with immune checkpoint inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma:Efficacy and systemic immune response[J].Front Immunol,2022,13:847601.
[23] 李若菲,白云飞,王芸姣,等.槲芪散可通过激活Hedgehog信号通路抑制大鼠肝癌前病变的形成[J].中国病理生理杂志,2017,33(4):661-668.
[24] 吴应强,叶久茂,范腾阳,等.丹参提取物对高血压性心脏病大鼠神经免疫的调节作用初探[J].中国免疫学杂志,2018,34(12):1826-1831.
[25] 马文军,刘江静,徐淑琴,等.复方丹参提取物对Hep瘤体及荷瘤小鼠免疫功能的影响[J].甘肃科技,2004,17(12):157-158.

相似文献/References:

[1]肖 岚,朱 宏,张 婷,等.董克礼教授治疗原发性肝癌临床经验*[J].陕西中医,2020,(11):1639.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.032]
　XIAO Lan,ZHU Hong,ZHANG Ting,et al.Experience of professor DONG Keli for treating primary liver cancer[J].,2020,(2):1639.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.032]
[2]王 军,徐建良,杜燕红.扶正祛邪汤对肝癌模型大鼠肠道菌群微生态环境的作用研究[J].陕西中医,2021,(2):143.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.002]
　WANG Jun,XU Jianliang,DU Yanhong.Effect of Fuzheng Quxie decoction on intestinal microflora microecological environment of liver cancer model rats[J].,2021,(2):143.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.002]
[3]朱玉辉,柴 劲.黄芪补气汤联合还原型谷胱甘肽对肝癌介入治疗后患者肝功能、氧化应激及炎症的影响[J].陕西中医,2021,(5):570.[doi:DOI:10.3969/j.issn.1000-7369.2020.05.006]
　ZHU Yuhui,CHAI Jin.Effect of Huangqi Buqi decoction combined with reduced glutathione on liver function,oxidative stress and inflammation after interventional therapy for hepatocellular carcinoma[J].,2021,(2):570.[doi:DOI:10.3969/j.issn.1000-7369.2020.05.006]
[4]刘振方,孙巧玉,孟祥彩,等.黄芩素下调微小RNA-130a抑制肝癌细胞侵袭机制研究[J].陕西中医,2021,(12):1667.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.003]
　LIU Zhenfang,SUN Qiaoyu,MENG Xiangcai,et al.Study on mechanism of baicalein down-regulating miR-130a to inhibit hepatocellular carcinoma invasion[J].,2021,(2):1667.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.003]
[5]李武浩,许尤琪.中医药防治肝动脉灌注化疗相关不良反应研究进展[J].陕西中医,2022,(5):673.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.031]
　LI Wuhao,XU Youqi.Clinical research progress of traditional Chinese medicine on the prevention and treatment of related adverse reaction of hepatic artery infusion chemotherapy[J].,2022,(2):673.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.031]
[6]陈 嵘,李淑敏,李旭华,等.软坚散结方调控小鼠HIF-1α 糖酵解分子转导抑制肝肿瘤细胞增殖机制研究[J].陕西中医,2023,(7):839.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.003]
　CHEN Rong,LI Shumin,LI Xuhua,et al.Mechanism study on Ruanjian Sanjie prescription inhibit proliferation of liver cancer cells through regulating HIF-1α pathway[J].,2023,(2):839.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.003]
[7]刘 鹏,陈青山,杨建波.柴胡疏肝散加减联合射频消融治疗肝癌疗效研究[J].陕西中医,2023,(7):892.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.015]
　LIU Peng,CHEN Qingshan,YANG Jianbo.Curative effect study on Chaihu Shugan powder combined with radiofrequency ablation for liver cancer[J].,2023,(2):892.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.015]
[8]张宏生,林月洁,陆凤娟.血府逐瘀汤加减联合盐酸吗啡缓释片治疗肝癌疼痛瘀血内阻证疗效研究[J].陕西中医,2023,(7):897.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.016]
　ZHANG Hongsheng,LIN Yuejie,LU Fengjuan.Clinical study on modified Xuefu Zhuyu decoction supplemented with morphine hydrochloride sustained-release tablets in treatment of liver cancer pain of Yuxue Neizu syndrome[J].,2023,(2):897.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.016]
[9]郭桓博,马瑞雪,朱正望,等.中药基于铁死亡机制防治肝癌研究进展[J].陕西中医,2024,(2):282.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.030]
　GUO Huanbo,MA Ruixue,ZHU Zhengwang,et al.Research progress in the prevention and treatment of liver cancer based on the mechanism of iron osis in traditional Chinese medicine[J].,2024,(2):282.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.030]
[10]李杳瑶,刘 华,孙铜林,等.鳖甲煎丸对肝癌大鼠黏着斑激酶/雷帕霉素靶蛋白通路的影响[J].陕西中医,2024,(3):308.[doi:DOI:10.3969/j.issn.1000-7369.2024.03.004]
　LI Yaoyao,LIU Hua,SUN Tonglin,et al.Effects of Biejia Jianwan on liver histopathological features and FAK/mTORC1 pathway in rats with hepatocellular carcinoma[J].,2024,(2):308.[doi:DOI:10.3969/j.issn.1000-7369.2024.03.004]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金资助项目(81473268); 贵州医科大学国家自然科学基金培育项目(19NSP012)
更新日期/Last Update: 2024-02-07